J.P. Morgan Exchange-Traded Fund Trust. Holdings as of Jul 31, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| AbbVie, Inc.ABBV | 7.85% | $712.17K | 2,838 |
| Eli Lilly & Co.LLY | 7.76% | $704.24K | 613 |
| UnitedHealth Group, Inc.UNH | 5.85% | $530.85K | 1,281 |
| AstraZeneca plc | 3.76% | $460.14K | 2,007 |
| Merck & Co., Inc.MRK | 4.82% | $437.34K | 3,359 |
| Johnson & JohnsonJNJ | 4.82% | $437.33K | 1,706 |
| Thermo Fisher Scientific, Inc.TMO | 3.73% | $338.84K | 590 |
| Bristol-Myers Squibb Co.BMY | 3.57% | $324.07K | 4,962 |
| Roche Holding AG | 2.82% | $316.82K | 586 |
| GSK plc | 2.47% | $301.57K | 8,605 |
| Abbott LaboratoriesABT | 3.11% | $282.11K | 2,669 |
| CVS Health Corp.CVS | 2.83% | $256.69K | 2,458 |
| Argenx SE | 2.06% | $215.31K | 218 |
| Stryker Corp.SYK | 2.23% | $201.93K | 620 |
| Danaher Corp.DHR | 2.16% | $196.15K | 1,006 |
| Cencora, Inc.COR | 2.07% | $188.05K | 604 |
| Novartis AG | 1.60% | $179.13K | 926 |
| Intuitive Surgical, Inc.ISRG | 1.93% | $175.25K | 496 |
| Edwards Lifesciences Corp.EW | 1.73% | $157.25K | 1,827 |
| IQVIA Holdings, Inc.IQV | 1.71% | $155.35K | 661 |
| Regeneron Pharmaceuticals, Inc.REGN | 1.60% | $144.90K | 190 |
| Biogen, Inc.BIIB | 1.56% | $141.86K | 699 |
| Cardinal Health, Inc.CAH | 1.51% | $137.33K | 597 |
| Fresenius SE & Co. KGaA | 1.04% | $108.52K | 1,831 |
| Centene Corp.CNC | 1.19% | $108.26K | 1,740 |
| Humana, Inc.HUM | 1.16% | $105.52K | 290 |
| Boston Scientific Corp.BSX | 1.07% | $96.68K | 2,069 |
| Insmed, Inc.INSM | 0.97% | $88.15K | 894 |
| Sartorius AG | 0.83% | $86.61K | 298 |
| Dyne Therapeutics, Inc.DYN | 0.82% | $74.73K | 2,968 |
| Vertex Pharmaceuticals, Inc.VRTX | 0.81% | $73.95K | 155 |
| Spyre Therapeutics, Inc.SYRE | 0.77% | $69.81K | 710 |
| Neurocrine Biosciences, Inc.NBIX | 0.73% | $66.55K | 399 |
| Bridgebio Pharma, Inc.BBIO | 0.73% | $65.83K | 822 |
| Alnylam Pharmaceuticals, Inc.ALNY | 0.70% | $63.92K | 311 |
| Align Technology, Inc.ALGN | 0.70% | $63.60K | 376 |
| Charles River Laboratories International, Inc.CRL | 0.66% | $60.22K | 259 |
| CG oncology, Inc.CGON | 0.62% | $56.31K | 791 |
| Ascendis Pharma A/S | 0.59% | $53.17K | 218 |
| Alumis, Inc.ALMS | 0.57% | $51.81K | 1,834 |
| LB Pharmaceuticals, Inc.LBRX | 0.56% | $50.42K | 1,258 |
| Teva Pharmaceutical Industries Ltd. | 1.60% | $47.54K | 4,084 |
| Disc Medicine, Inc.IRON | 0.51% | $46.20K | 600 |
| PTC Therapeutics, Inc.PTCT | 0.49% | $44.75K | 658 |
| Bicara Therapeutics, Inc.BCAX | 0.44% | $40.22K | 1,484 |
| Arcus Biosciences, Inc.RCUS | 0.43% | $39.01K | 1,384 |
| Novo Nordisk A/S | 2.61% | $36.59K | 5,014 |
| Erasca, Inc.ERAS | 0.39% | $35.50K | 1,956 |
| Damora Therapeutics, Inc. | 0.37% | $33.80K | 1,166 |
| Argenx SE | 0.30% | $31.61K | 32 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.